Arcutis Biotherapeutics Inc Total Liabilities
Arcutis Biotherapeutics Inc total liabilities. Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has total liabilities worth $267.96 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Arcutis Biotherapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Arcutis Biotherapeutics Inc (2017–2025)
Total liabilities of Arcutis Biotherapeutics Inc from 2017 to 2025. This chart illustrates how Arcutis Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Arcutis Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Hawaiian Inc
NASDAQ:FHB
|
USA | $20.82 Billion |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
China | CN¥-3.48 Billion |
|
Hilton Grand Vacations Inc
NYSE:HGV
|
USA | $10.59 Billion |
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
China | CN¥31.14 Billion |
|
Escorts Kubota Limited
NSE:ESCORTS
|
India | Rs31.83 Billion |
|
Park National Corporation
NYSE MKT:PRK
|
USA | $8.45 Billion |
|
Freshpet Inc
NASDAQ:FRPT
|
USA | $574.72 Million |
|
BankUnited Inc
NYSE:BKU
|
USA | $31.88 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Arcutis Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Arcutis Biotherapeutics Inc asset portfolio.
Liquidity & Leverage Metrics
Arcutis Biotherapeutics Inc Total Liabilities Ratios Explained
Arcutis Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcutis Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Arcutis Biotherapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $243.49 Million | +27.25% |
| 2024-12-31 | $191.35 Million | -24.28% |
| 2023-12-31 | $252.70 Million | +5.43% |
| 2022-12-31 | $239.69 Million | +116.97% |
| 2021-12-31 | $110.47 Million | +299.58% |
| 2020-12-31 | $27.65 Million | +398.16% |
| 2019-12-31 | $5.55 Million | -92.61% |
| 2018-12-31 | $75.08 Million | +752.08% |
| 2017-12-31 | $8.81 Million | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more